Carbonic anhydrase III is insufficient in muscles of myasthenia gravis patients

Autoimmunity

Volumn 42, Issue 3, 2009, Pages 209-215

  Du, Ai Lian ^a,b   Ren, Hui Min ^b   Lu, Chuan Zhen ^b   Tu, Jiang Long ^c   Xu, Cong Feng ^d   Sun, Yong An ^e  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c NANCHANG UNIVERSITY   (China)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Carbonic anhydrase III; Insufficient; MALDI TOF; Myasthenia gravis; Skeletal muscle

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CARBONATE DEHYDRATASE III; PROTEIN P25; ANTISERUM; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME DEFICIENCY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MUSCLE CELL; MYASTHENIA GRAVIS; PECTORALIS MAJOR MUSCLE; SKELETAL MUSCLE; CYTOPLASM; ENZYMOLOGY; FAST MUSCLE FIBER; IMMUNOLOGY; MIDDLE AGED; PEPTIDE MAPPING; SLOW MUSCLE FIBER;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; CARBONIC ANHYDRASE III; CYTOPLASM; FEMALE; HUMANS; IMMUNE SERA; MALE; MIDDLE AGED; MUSCLE CELLS; MUSCLE FIBERS, FAST-TWITCH; MUSCLE FIBERS, SLOW-TWITCH; MUSCLE, SKELETAL; MYASTHENIA GRAVIS; PECTORALIS MUSCLES; PEPTIDE MAPPING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; YOUNG ADULT;

EID: 67649650135     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930802668610     Document Type: Article

References (41)

1. Lindstrom, JM, Seybold, ME, Lennon, VA, Whittingham, S. and Duane, DD (1976) Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology, 26, pp. 1054-1059.
2. Vincent, A., Palace, J. and Hilton-Jones, D. (2001) Myasthenia gravis. Lancet, 357, pp. 2122-2128.
3. Conti-Fine, BM, Milani, M. and Kaminski, HJ (2006) Myasthenia gravis: Past, present, and future. J Clin Invest, 116, pp. 2843-2854.
4. Soliven, BC, Lange, DJ, Penn, AS, Younger, D., Jaretzki, A., Lovelace 3rd, RE and Rowland, LP (1988) Seronegative myasthenia gravis. Neurology, 38, pp. 514-517.
5. Vincent, A., Bowen, J., Newsom-Davis, J. and McConville, J. (2003) Seronegative generalised myasthenia gravis: Clinical features, antibodies, and their targets. Lancet Neurol, 2, pp. 99-106.
6. Hoch, W., McConville, J., Helms, S., Newsom-Davis, J., Melms, A. and Vincent, A. (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med, 7, pp. 365-368.
7. Skeie, GO, Lunde, PK, Sejersted, OM, Mygland, A., Aarli, JA and Gilhus, NE (2001) Autoimmunity against the ryanodine receptor in myasthenia gravis. Acta Physiol Scand, 171, pp. 379-384.
8. Yamamoto, AM, Gajdos, P., Eymard, B., Tranchant, C., Warter, JM, Gomez, L., Bourquin, C., Bach, JF and Garchon, HJ (2001) Anti-titin antibodies in myasthenia gravis: Tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol, 58, pp. 885-890.
9. Shiraishi, H., Motomura, M., Yoshimura, T., Fukudome, T., Fukuda, T., Nakao, Y., Tsujihata, M., Vincent, A. and Eguchi, K. (2005) Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol, 57, pp. 289-293.
10. Kuwabara, S., Nemoto, Y., Misawa, S., Takahashi, H., Kawaguchi, N. and Hattori, T. (2007) Anti-MuSK-positive myasthenia gravis: Neuromuscular transmission failure in facial and limb muscles. Acta Neurol Scand, 115, pp. 126-128.
11. Xu, K., Jha, S., Hoch, W. and Dryer, S. (2006) Delayed synapsing muscles are more severely affected in an experimental model of MuSK-induced myasthenia gravis. Neuroscience, 143, pp. 655-659.
12. Yeh, JH, Chen, WH, Chiu, HC and Vincent, A. (2004) Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology, 62, pp. 2131-2132.
13. Ren, HM, Zhou, ZG, Chen, XJ, Huang, J. and Lu, CZ (2000) Analysis of protein components of skeletal muscle from the patients with myasthenia gravis. Chin J Neurol, 33, pp. 227-230.
14. Ren, HM, Zhou, ZG, Chen, XJ, Huang, J. and Lu, CZ (2000) Comparison of protein components in normal and myasthenia gravis skeletal muscles. Chin J Clin Neurosci, 8, pp. 260-262.
15. Ren, HM, Lu, CZ, Zhou, ZG, Chen, XJ and Huang, J. (2002) Analysis of 25 kD protein content of skeletal muscles from the patients with myasthenia gravis. Chin J Neurol, 35, pp. 32-35.
16. Marvin, LF, Roberts, MA and Fay, LB (2003) Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in clinical chemistry. Clin Chim Acta, 337, pp. 11-21.
17. Robert-Pachot, M., Desbos, A., Moreira, A., Becchi, M., Tebib, J., Bonnin, M., Aitsiselmi, T., Bienvenu, J. and Fabien, N. (2007) Carbonic anhydrase III: A new target for autoantibodies in autoimmune diseases. Autoimmunity, 40, pp. 380-389.
18. Robert-Pachot, M., Desbos, A., Moreira, A., Becchi, M., Tebib, J., Bonnin, M., Aitsiselmi, T., Bienvenu, J. and Fabien, N. (2007) A new target for autoantibodies in patients with rheumatoid arthritis. Ann NY Acad Sci, 1108, pp. 382-391.
19. Jaretzki, A., Barohn, RJ, Ernstoff, RM, Kaminski, HJ, Keesey, JC, Penn, AS and Sanders, DB (2000) Myasthenia gravis: Recommendations for clinical research standards. Neurology, 55, pp. 16-23.
20. Fernandez-Patron, C., Hardy, E., Sosa, A., Seoane, J. and Castellanos, L. (1995) Double staining of Coomassie blue-stained polyacrylamide gels by immidazole-sodium dodecylsulfate-zinc reverse staining: Sensitive detection of Coomassie blue-undetected proteins. Anal Biochem, 224, pp. 263-269.
21. Spector, T. (1978) Refinement of Coomassie blue method of protein quantitation: A simple and linear spectrophotometric assay for less than or equal to 0.5 to 50 microgram of protein. Anal Biochem, 86, pp. 142-146.
22. Debus, E., Weber, K. and Osborn, M. (1983) Monoclonal antibodies to desmin, the muscle specific intermediate filament protein. EMBO J, 2, pp. 2305-2312.
23. Towbin, H., Staehelin, T. and Gordon, J. (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA, 76, pp. 4350-4354.
24. Funatsu, T., Higuchi, H. and Ishiwata, S. (1990) Elastic filaments in skeletal muscle revealed by selective removal of titin filaments with plasma gelsolin. J Cell Biol, 110, pp. 53-62.
25. Brooke, MH and Kaiser, KK (1970) Muscle fiber types: How many and what kind?. Arch Neurol, 23, pp. 369-379.
26. Vincent, A. (2002) Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol, 2, pp. 797-804.
27. Lindstrom, JM, Schelton, D. and Fujii, Y. (1988) Myasthenia gravis. Adv Immunol, 42, pp. 233-284.
28. Drachman, DB (1994) Myasthenia gravis. N Engl J Med, 330, pp. 1797-1810.
29. Vaananen, HK, Paloniemi, M. and Vuori, J. (1985) Purification and localization of human carbonic anhydrase III. Typing of skeletal muscle fibres in paraffin embedded section. Histochemistry, 83, pp. 231-235.
30. Cabiscol, E. and Levine, RL (1995) Carbonic anhydrase III. J Biol Chem, 270, pp. 14742-14747.
31. Carter, N., Jeffery, S., Shiels, A., Edwards, Y., Tipler, T. and Hopkinson, DA (1979) Characterization of human carbonic anhydrase III from skeletal muscle. Biochem Genet, 17, pp. 837-854.
32. Lioyd, J., McMillan, S., Hopkinson, D. and Edwards, YH (1986) Nucleotide sequence and derived amino acid sequence of a cDNA encoding human muscle carbonic anhydrase. Gene, 41, pp. 233-239.
33. Gros, G. and Dodgson, SJ (1988) Velocity of CO2 exchange in muscle and liver. Ann Rev Physiol, 50, pp. 669-694.
34. Cote, CH, Perreault, G. and Frenette, J. (1997) Carbohydrate utilization in rat soleus muscle is influenced by carbonic anhydrase III activity. Am J Physiol Regul Integr Comp Physiol R, 273, pp. 1211-1218.
35. Geers, C., Benz, K. and Gros, G. (1995) Effects of carbonic anhydrase inhibitors on oxygen consumption and lactate accumulation in skeletal muscle. Comp Biochem Physiol A: Physiol, 112, pp. 111-117.
36. Geers, C. and Gros, G. (1990) Effects of carbonic anhydrase inhibitors on contraction, intracellular pH and energy-rich phosphates of rat skeletal muscle. J Physiol, 423, pp. 279-297.
37. Zimmerman, U-J, Wang, PW, Zhang, X., Bogdanovich, S. and Forster, R. (2004) Anti-oxidative response of carbonic anhydrase III in skeletal muscle. IUBMB Life, 56, pp. 343-347.
38. Inagaki, Y., Jinno-Yoshida, Y., Hamasaki, Y. and Ueki, H. (1991) A novel autoantibody reactive with carbonic anhydrase in sera from patients with systemic lupus erythematosus and Sjogren's syndrome. J Dermotol Sci, 2, pp. 147-154.
39. Sly, WS, Hewett-Emmett, D., Whyte, MP, Yu, YSL and Tashian, RE (1983) Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci USA, 80, pp. 2752-2756.
40. Gailly, P., Jouret, F., Martin, D., Debaix, H., Parreira, KS, Nishita, T., Blanchard, A., Antignac, C., Willnow, TE, Courtoy, PJ, Scheinman, SJ, Christensen, EI and Devuyst, O. (2008) A novel renal carbonic anhydrase type III plays a role in proximal tubule dysfunction. Kidney Int, 74, pp. 52-61.
41. Carmignani, M., Scoppetta, C. and Ranelletti, F. (1984) Adverse interaction between acetazolamide and anticholinesterase drugs at the normal and myasthenic neuromuscular junction level. Int J Clin Pharmacol Ther Toxicol, 22, pp. 140-144.